Home > Boards > US OTC > Cannabis > Khiron Life Sciences Corp (KHRNF)
Followed By 22
Posts 4708
Boards Moderated 1
Alias Born 12/21/2016

Saturday, August 07, 2021 11:07:34 PM

Re: None

Post# of 2376
Khiron Welcomes Dr. Eduardo Faveret as Medical Director for Brazil
July 29, 2021·4 min read
In this article:

KHRNF
-2.32%

In 2013, Dr. Faveret became one of the first Brazilian physicians to prescribe medical cannabis, subsequently treating more than 3,000 patients with various conditions across the country

As Medical Director for Zerenia™, Dr. Faveret will lead patient prescriptions, physician outreach and education, and data-driven product development for Khiron in Brazil, leveraging relationships and deep medical cannabis expertise developed throughout 30-year career

Khiron positioned to expand Zerenia™ clinics in key cities in Brazil following addition of Medical Director and first sales in Brazil in early July, leveraging Brazilian marketing agreements and production, distribution, and clinical assets in Latin America

Brazil is Latin America's largest addressable market, with over 200 million people and the potential to reach USD$1.4 billion in annual revenues (Source: New Frontier Data)

TORONTO, July 29, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN)(OTCQX:KHRNF)(Frankfurt:A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the addition of renowned physician, pediatric neurologist and clinical physiologist, Dr. Eduardo Faveret, as Medical Director for Zerenia™ Brazil. As the Company expands its global leadership position, the addition of Dr. Faveret represents a major milestone toward bringing Khiron's market validated clinic strategy to larger markets in Latin America.
Dr. Eduardo Faveret, Medical Director Zerenia™ Brazil
Dr. Faveret is a prominent advocate for medical cannabis in Brazil and a leading prescriber in the country of more than 200 million people. In 2013, Dr. Faveret became one of the first physicians in Brazil to prescribe medical cannabis extract to a child, subsequently treating more than 3,000 patients with conditions such as Alzheimer's, Parkinson's, MS, cancer, anxiety, depression, insomnia, Tourette's syndrome, autism, and chronic pain, among others.

Dr. Faveret boasts a highly distinguished medical and academic career, as the founder and former medical director of the Epilepsy Center at the Paulo Niemeyer State Brain Institute in Rio de Janeiro. He completed post-graduate studies in Pediatric Neurology (Federal University of Rio de Janeiro and FIOCRUZ) and specialized in Clinical Neurophysiology and Epileptology in Bonn Universität and Bethel Epilepsie Zentrum in Germany.

Management Commentary
Alvaro Torres, Khiron CEO and Director, commented: "We are thrilled to welcome Dr. Faveret to our team. With over eight years' experience helping patients access medical cannabis, Dr. Faveret is a leading medical cannabis specialist in Brazil who shares our mission of improving patients' lives through medical cannabis. With the goal of establishing ourselves as the dominant B2C medical cannabis company in Latin America and Europe, and having proven our ability to supply Khiron-branded product to Brazilian patients, we look forward to working with Dr. Faveret to deliver our proven vertically integrated strategy in Latin America's largest market."

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.



Recent KHRNF News

IGEN Networks Corporation wins award to provide Medallion GPS to New York State Counties IGEN Jun 24, 2022 6:00 AM

BOX Pure Air Supplies Highland Park Independent School District (TX) AIRBOX ™ Air Purification Units Improving Air Quality in Schools SING Jun 23, 2022 1:05 PM

Gaensel Energy Group, Inc. (GEGR) Presents Its Partners and Activities of Its CONSORZIO GREEN SOLUTION & GNL GEGR Jun 23, 2022 11:40 AM

Resgreen Group Announces Major Milestone with LilBuddy ™ Pilot Testing RGGI Jun 23, 2022 7:07 AM

Demand Brands engages BF Borgers CPA PC as auditor DMAN Jun 22, 2022 9:11 AM

Global Fiber Technologies, Inc., Closes its First Round of Inventory Financing. GFTX Jun 22, 2022 9:00 AM

Maison Luxe Appoints Aether Diamonds CEO Ryan Shearman to Its Board of Directors MASN Jun 22, 2022 8:54 AM

Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC KTTA Jun 22, 2022 8:07 AM

Amesite Launches V5 Platform, Enabling Every Business, University and Museum to Deliver or Sell AI-Powered, Branded eLearning AMST Jun 22, 2022 7:34 AM

Dalrada Financial Corporation Appoints Brian McGoff as President and Chief Operating Officer DFCO Jun 21, 2022 9:30 AM

Global Arena Holding Initiates 1 for 12 Reverse in Support of Potential Capital and Growth Endeavors GAHC Jun 21, 2022 7:21 AM

Hillcrest Investor Technology Poised For Central Role In The Reimagined Energy Future HLRTF Jun 20, 2022 6:04 AM

Co Brand Partners Investing in Social Revolution Jun 17, 2022 4:00 AM

Resgreen Group Announces Release of Significant Update to BotWay ™ Fleet and Management System RGGI Jun 16, 2022 6:00 AM

GoDaddy Founder, Bob Parsons Details Journey of Healing Through Psychedelics in Exclusive Interview With PSYC PSYC Jun 15, 2022 8:30 AM

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y